Entero Therapeutics Inc (NASDAQ: ENTO) is -48.71% lower on its value in year-to-date trading and has touched a low of $0.19 and a high of $1.27 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ENTO stock was last observed hovering at around $0.53 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $0.55, the stock is 15.37% and 25.63% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 20.98 million and changing 3.53% at the moment leaves the stock 9.89% off its SMA200. ENTO registered -11.77% loss for a year compared to 6-month loss of -11.48%. The firm has a 50-day simple moving average (SMA 50) of $0.43682 and a 200-day simple moving average (SMA200) of $0.49942.
The stock witnessed a 5.54% gain in the last 1 month and extending the period to 3 months gives it a 12.00%, and is 40.54% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 17.91% over the week and 15.56% over the month.
Entero Therapeutics Inc (ENTO) has around 2 employees, a market worth around $2.62M and $0.00M in sales. Distance from 52-week low is 196.65% and -56.79% from its 52-week high. The company has generated returns on investments over the last 12 months (-44.60%).
9.0 institutions hold shares in Entero Therapeutics Inc (ENTO), with institutional investors hold 3.31% of the company’s shares. The shares outstanding are 4.77M, and float is at 4.44M with Short Float at 6.45%. Institutions hold 3.07% of the Float.
Entero Therapeutics Inc (ENTO) Insider Activity
The most recent transaction is an insider sale by Romano Sarah, the company’s Chief Financial Officer. SEC filings show that Romano Sarah sold 727 shares of the company’s common stock on Jan 06 ’25 at a price of $0.64 per share for a total of $465.0. Following the sale, the insider now owns 17287.0 shares.
Entero Therapeutics Inc disclosed in a document filed with the SEC on Oct 09 ’24 that Romano Sarah (Chief Financial Officer) sold a total of 476 shares of the company’s common stock. The trade occurred on Oct 09 ’24 and was made at $0.45 per share for $212.0. Following the transaction, the insider now directly holds 18014.0 shares of the ENTO stock.
